A citation-based method for searching scientific literature

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli, Jessica Read, Peter Langmuir, Anderson J Ryan, Martin J Schlumberger. J Clin Oncol 2012
Times Cited: 839



Cabozantinib in progressive medullary thyroid cancer.
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, Patrick Schöffski, Marcia S Brose, Manisha H Shah, Lisa Licitra, Barbara Jarzab, Viktor Medvedev, Michael C Kreissl, Bruno Niederle, Ezra E W Cohen, Lori J Wirth, Haythem Ali, Colin Hessel, Yifah Yaron, Douglas Ball, Barry Nelkin, Steven I Sherman. J Clin Oncol 2013
Times Cited: 648




List of shared articles



Times cited

Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Poupak Fallahi, Silvia Martina Ferrari, Maria Rosaria Galdiero, Gilda Varricchi, Giusy Elia, Francesca Ragusa, Sabrina Rosaria Paparo, Salvatore Benvenga, Alessandro Antonelli. Semin Cancer Biol 2022
20

Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial.
Lori J Wirth, Bruce Robinson, Valentina Boni, Daniel S W Tan, Caroline McCoach, Erminia Massarelli, Lisa M Hess, Min-Hua Jen, Jennifer Kherani, Elizabeth Olek,[...]. Oncologist 2022
2

Updates on therapy for medullary thyroid cancer in 2021.
Marie Puerto, Françoise Borson-Chazot, Antoine Tabarin. Ann Endocrinol (Paris) 2022
1

Surgical aspects and controversies in the management of medullary thyroid cancer.
Katerina Green, Justin Hintze, James Paul O'Neill. Ir J Med Sci 2022
0

Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose.
Lingtian Zhang, Marialuisa Moccia, David C Briggs, Jaideep B Bharate, Naga Rajiv Lakkaniga, Phillip Knowles, Wei Yan, Phuc Tran, Anupreet Kharbanda, Xiuqi Wang,[...]. J Med Chem 2022
0

CONUT Score: A New Tool for Predicting Prognosis in Patients with Advanced Thyroid Cancer Treated with TKI.
Cristina Dalmiglio, Lucia Brilli, Michele Campanile, Cristina Ciuoli, Alessandra Cartocci, Maria Grazia Castagna. Cancers (Basel) 2022
1

Clinical Application of Next-Generation Sequencing in Advanced Thyroid Cancers.
Lucy X Ma, Osvaldo Espin-Garcia, Philippe L Bedard, Tracy Stockley, Rebecca Prince, Ozgur Mete, Monika K Krzyzanowska. Thyroid 2022
0

In silico Analysis of Publicly Available Transcriptomics Data Identifies Putative Prognostic and Therapeutic Molecular Targets for Papillary Thyroid Carcinoma.
Asma Almansoori, Poorna Manasa Bhamidimarri, Riyad Bendardaf, Rifat Hamoudi. Int J Gen Med 2022
0

Stereotactic radiotherapy (SRT) for differentiated thyroid cancer (DTC) oligometastases: an AIRO (Italian association of radiotherapy and clinical oncology) systematic review.
Valentina Lancellotta, Giuseppe Fanetti, Fabio Monari, Monica Mangoni, Renzo Mazzarotto, Luca Tagliaferri, Carlo Gobitti, Elisa Lodi Rizzini, Sara Talomo, Irene Turturici,[...]. Radiol Med 2022
0

Effect of Vandetanib Treatment on Cystic Changes in the Liver following Metastasis from Medullary Thyroid Carcinoma.
Ai Matsui, Soji Toda, Daisuke Murayama, Hiroyuki Iwasaki. Case Rep Endocrinol 2022
0

An Audit of Systemic Therapy in Medullary Carcinoma Thyroid.
Aditya Pavan Kumar Kanteti, George Abraham, Vijay M Patil, Nandini Menon, Tanmoy Mandal, Sobin V Jacob, Keshav Garg, Anbarasan Sekar, Rup Jyoti Sarma, Laxma Reddy Mekala,[...]. Indian J Surg Oncol 2022
0

Practical lessons from treating medullary thyroid carcinoma patients harboring a RET-alteration: Pralsetinib-induced acute confusional state.
Eliya Shachar, Shira Peleg Hasson, Deborah T Blumenthal, Meerav Fraenkel, Yoel Uri, Ido Wolf, Simona Grozinsky-Glasberg. Acta Oncol 2022
0

T cells engineered to express immunoreceptors targeting the frequently expressed medullary thyroid cancer antigens calcitonin, CEA and RET M918T.
Timothy Erickson, Yi-Ping Shih, Joseph Fass, Myungkyu Jang, Eric Tran. Thyroid 2022
0

Thyroid Cancer and COVID-19: Prospects for Therapeutic Approaches and Drug Development.
Na Qu, Zongguang Hui, Zhixin Shen, Chengxia Kan, Ningning Hou, Xiaodong Sun, Fang Han. Front Endocrinol (Lausanne) 2022
0

Targeted therapy and drug resistance in thyroid cancer.
Yujie Zhang, Zhichao Xing, Tianyou Liu, Minghai Tang, Li Mi, Jingqiang Zhu, Wenshuang Wu, Tao Wei. Eur J Med Chem 2022
0

Pharmacogenetic Review: Germline Genetic Variants Possessing Increased Cancer Risk With Clinically Actionable Therapeutic Relationships.
Austin A Saugstad, Natasha Petry, Catherine Hajek. Front Genet 2022
0

Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism.
Alessio Basolo, Antonio Matrone, Rossella Elisei, Ferruccio Santini. Semin Cancer Biol 2022
8

Multiple endocrine neoplasia type 2: A review.
Jes Sloth Mathiesen, Grigoris Effraimidis, Maria Rossing, Åse Krogh Rasmussen, Lise Hoejberg, Lars Bastholt, Christian Godballe, Peter Oturai, Ulla Feldt-Rasmussen. Semin Cancer Biol 2022
5

A contemporary review of rearranged during transfection-selective inhibitors.
Angel W Liu, Connie Liang, Chung-Shien Lee. J Oncol Pharm Pract 2022
1

Discovery, preclinical development, and clinical application of pralsetinib in the treatment of thyroid cancer.
Pietro Locantore, Roberto Novizio, Andrea Corsello, Rosa Maria Paragliola, Alfredo Pontecorvi, Salvatore Maria Corsello. Expert Opin Drug Discov 2022
2

Outcomes of Advanced Medullary Thyroid Carcinoma in the Era of Targeted Therapy.
Nicholas L Kesby, Alexander J Papachristos, Matti Gild, Ahmad Aniss, Mark S Sywak, Roderick Clifton-Bligh, Stan B Sidhu, Anthony R Glover. Ann Surg Oncol 2022
2

The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with RET alterations.
Steve Duff, Francesca Bargiacchi, Chelsea Norregaard, Melanie Brener, Erin Sullivan. J Manag Care Spec Pharm 2022
0

Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging.
Heying Duan, Andrei Iagaru, Carina Mari Aparici. Nanotheranostics 2022
0

Real-world insights into the efficacy and safety of tyrosine kinase inhibitors against thyroid cancers.
Lingyu Li, Lin Cheng, Ri Sa, Xian Qiu, Libo Chen. Crit Rev Oncol Hematol 2022
1

Multiple endocrine neoplasia 2: an overview.
B Saravana-Bawan, J D Pasternak. Ther Adv Chronic Dis 2022
0

American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment.
David C Shonka, Alan Ho, Ashish V Chintakuntlawar, Jessica L Geiger, Jong C Park, Nagashree Seetharamu, Sina Jasim, Amr H Abdelhamid Ahmed, Keith C Bible, Marcia S Brose,[...]. Head Neck 2022
1

Nutrition in Advanced Thyroid Cancer Patients.
Laura Agate, Elisa Minaldi, Alessio Basolo, Valentina Angeli, Roberta Jaccheri, Ferruccio Santini, Rossella Elisei. Nutrients 2022
0

Cancer combination therapies by angiogenesis inhibitors; a comprehensive review.
Mohammad Javed Ansari, Dmitry Bokov, Alexander Markov, Abduladheem Turki Jalil, Mohammed Nader Shalaby, Wanich Suksatan, Supat Chupradit, Hasan S Al-Ghamdi, Navid Shomali, Amir Zamani,[...]. Cell Commun Signal 2022
0

Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.
Antonio Matrone, Carla Gambale, Alessandro Prete, Rossella Elisei. Front Endocrinol (Lausanne) 2022
1

Systemic Therapy in Thyroid Cancer.
Amit Kumar Agrawal, Vanita Noronha, Vijay Patil, Nandini Menon, Akhil Kapoor, Anuradha Chougule, Pratik Chandrani, Kumar Prabhash. Indian J Surg Oncol 2022
0

ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer.
S Filetti, C Durante, D M Hartl, S Leboulleux, L D Locati, K Newbold, M G Papotti, A Berruti. Ann Oncol 2022
0

The pathogenesis and treatment differences between differentiated thyroid carcinoma and medullary thyroid carcinoma.
Jingyang Su, Yue Fu, Menglei Wang, Jiang Yan, Shengyou Lin. Curr Med Res Opin 2022
0

Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer.
Francesca Ragusa, Silvia Martina Ferrari, Giusy Elia, Sabrina Rosaria Paparo, Eugenia Balestri, Chiara Botrini, Armando Patrizio, Valeria Mazzi, Giovanni Guglielmi, Rudy Foddis,[...]. Int J Mol Sci 2022
0

The Role of the Kinase Inhibitors in Thyroid Cancers.
Francesca Cuomo, Claudio Giani, Gilda Cobellis. Pharmaceutics 2022
0

Thyroid Dysfunction from Treatments for Solid Organ Cancers.
Anupam Kotwal, Donald S A McLeod. Endocrinol Metab Clin North Am 2022
0

A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer.
Julie E Bauman, Zhengjia Chen, Chao Zhang, James P Ohr, Robert L Ferris, Gerald M McGorisk, Stephen Brandt, Sumathi Srivatsa, Amy Y Chen, Conor E Steuer,[...]. Cancers (Basel) 2022
0

Proteinuria is a late-onset adverse event in patients treated with cabozantinib.
V Cappagli, D Moriconi, A G Bonadio, D Giannese, Gaetano La Manna, M Francesca Egidi, G Comai, G Vischini, V Bottici, R Elisei,[...]. J Endocrinol Invest 2021
6

Anti-angiogenic Agents: A Review on Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors.
Kang Cheng, Chen-Fu Liu, Guo-Wu Rao. Curr Med Chem 2021
3

Octreotide and pasireotide effects on medullary thyroid carcinoma (MTC) cells growth, migration and invasion.
E Giardino, R Catalano, F Mangili, A M Barbieri, D Treppiedi, F M Elli, A Dolci, A Contarino, A Spada, M Arosio,[...]. Mol Cell Endocrinol 2021
2

Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA.
C M Della Corte, F Morgillo. ESMO Open 2021
4

Improvement of Overall Survival Using TKIs as Salvage Therapy in Advanced Thyroid Carcinoma: Real-Life Data on a Single Center Experience.
Lucia Brilli, Cristina Dalmiglio, Tania Pilli, Filomena Barbato, Fabio Maino, Marco Capezzone, Alessandra Cartocci, Maria Grazia Castagna. J Clin Med 2021
2

Molecular-Driven Therapy in Advanced Thyroid Cancer.
Kevin C Miller, Ashish V Chintakuntlawar. Curr Treat Options Oncol 2021
1

Thyroid cancer and COVID-19: experience at one single thyroid disease referral center.
Alessandro Prete, Marco Falcone, Valeria Bottici, Carlotta Giani, Giusy Tiseo, Laura Agate, Antonio Matrone, Virginia Cappagli, Laura Valerio, Loredana Lorusso,[...]. Endocrine 2021
6

Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model.
Silvia Carra, Germano Gaudenzi, Alessandra Dicitore, Davide Saronni, Maria Celeste Cantone, Alice Plebani, Anna Ghilardi, Maria Orietta Borghi, Leo J Hofland, Luca Persani,[...]. Int J Mol Sci 2021
0

Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial.
Dapeng Li, Yihebali Chi, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng,[...]. Clin Cancer Res 2021
10

Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy.
Carrie C Lubitz, Peter M Sadow, Gilbert H Daniels, Lori J Wirth. Thyroid 2021
5

Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?
Sergio Di Molfetta, Andrea Dotto, Giuseppe Fanciulli, Tullio Florio, Tiziana Feola, Annamaria Colao, Antongiulio Faggiano. Front Endocrinol (Lausanne) 2021
3

Benefits and Limitations of TKIs in Patients with Medullary Thyroid Cancer: A Systematic Review and Meta-Analysis.
Zoe A Efstathiadou, Charalambos Tsentidis, Alexandra Bargiota, Vasiliki Daraki, Kalliopi Kotsa, Georgia Ntali, Labrini Papanastasiou, Stelios Tigas, Konstantinos Toulis, Kalliopi Pazaitou-Panayiotou,[...]. Eur Thyroid J 2021
4

Intraductal carcinoma of the salivary gland with NCOA4-RET: expanding the morphologic spectrum and an algorithmic diagnostic approach.
Adam S Fisch, Israa Laklouk, Masato Nakaguro, Vânia Nosé, Lori J Wirth, Daniel G Deschler, William C Faquin, Dora Dias-Santagata, Peter M Sadow. Hum Pathol 2021
2

Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial.
L Marandino, D Raggi, G Calareso, A Alessi, M Colecchia, A Martini, A Briganti, F Montorsi, R Madison, J S Ross,[...]. Clin Genitourin Cancer 2021
1


Longstocking, LLC. © 2021
Home | About Us | FAQs | Terms & Privacy